Loading
Latest filing published 25 Jun 2026 for 한화생명. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by 케이비인베스트먼트 span 4 companies, the busiest being 한화생명, 아이엠바이오로직스 and 지니너스. Between 7 August 2024 and 25 June 2026, the trades on record add up to 7 filings.
On the open market, the record shows 5 purchases and 2 sales worth €4.9M. The totals do not cover 6 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 3 purchases and 2 sales.
None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.
The newest entry dates from 25 June 2026: an open-market purchase, in 한화생명. Between a trade and the moment it shows up on DART (FSS), the median delay is 2 days. That lag is the time during which only the insider knows about the trade. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations